Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.
02552.HK stock price ended at $3.21 on 星期二, after rising 0.94%
On the latest trading day Jan 20, 2026, the stock price of 02552.HK rose by 0.94%, climbing from $3.16 to $3.21. Throughout the session, the stock experienced a volatility of 1.90%, with prices fluctuating between a daily low of $3.16 and a high of $3.22. Alongside this price increase, trading volume also rose by 3.9M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 102.0K shares were traded, amounting to a market value of approximately $3.1B.